- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00094601
Relationship of Dopamine to Cognitive Function in Parkinson's Disease
Cognitive Function in Parkinson's Disease: Relationship to Cortical Dopamine Synthesis and Dopamine D1 Receptors
This study will examine how the brain chemical dopamine affects memory, reasoning, and other thought processes in people with Parkinson's disease with and without dementia and in healthy control subjects.
Healthy normal volunteers and people with Parkinson's disease who are between 40 and 85 years of age may be eligible for this study. Pregnant women with Parkinson's disease and breastfeeding normal volunteers are excluded. Candidates are screened with a physical and neurological examination, blood tests, a brief mental test called the Mini Mental Status Examination, and other tests designed to assess memory, learning, reasoning, and other thought processes. Patients with Parkinson's disease also undergo a more thorough mental evaluation called the Mattis Dementia Rating Scale. The study requires about 15 hours over 4 or 5 outpatient visits to NIH.
Participants undergo two positron emission tomography (PET) scans on two separate days and a magnetic resonance imaging (MRI) scan, as follows:
PET Scans
The two PET procedures are done the same way, except one uses a radioactive tracer called [(18)F]DOPA and one uses a tracer called [(11)C]NNC-112. A catheter (small plastic tube) is placed in a vein in the subject's arm for injection of the tracer. The subject lies on the scanner bed and a special mask is fitted to his or her head to hold it in place during the procedure. Just before injecting the tracer, a 10-minute "transmission scan" is done of the head using a tracer called (68)Ge. Then, a series of scans using one of the two study tracers ([(18)F]DOPA or [(11)C]NNC-112 are done for about 90 minutes. About 1 hour before injection of the [(18)F]DOPA tracer, subjects take 200 mg of the drug carbidopa by mouth to help the tracer work properly. Blood pressure, breathing and heart are monitored before and after injection of the [(11)C]NNC-112 tracer.
Patients with Parkinson's disease are taken off all Parkinson's medications the night before the [(18)F]DOPA scan and their motor function is tested the following morning before the scans are done, using the Unified Parkinson's Disease Rating Scale. Patients can resume all medications except L-DOPA (including Sinemet) after the movement test, and they can resume L-DOPA after the PET scan is finished.
MRI Scan
MRI uses a strong magnetic field and radio waves to obtain images of the brain. The subject lies still on a table that slides inside the scanner, a metal cylinder. They wear ear plugs to muffle loud knocking sounds that occur during the scanning and can communicate with the MRI staff at any time through an intercom.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Tipo de estudio
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
- INCLUSION CRITERIA:
PD patients must meet the diagnosis of idiopathic Parkinson's disease. Diagnosis will be based upon the presence of at least two of the four cardinal symptoms (tremor, bradykinesia, rigidity and instability) as well as a positive response to dopaminergic agents.
Patients will be on stable dopaminergic therapy for approximately two weeks prior to enrollment.
Control subjects must be healthy and aged 40 - 85 years and will be age and gender matched to PD patients.
EXCLUSION CRITERIA - CONTROLS:
Diagnosis of idiopathic Parkinson's disease.
Secondary cause of Parkinsonism, e.g. Wilson's disease, neuroleptic use.
Psychiatric disease that would, in judgment of the investigator, interfere with the safe conduct of the study.
Current psychiatric illness.
Severe depressive symptoms with BDI 16+.
Substance abuse, severe systemic disease, poor vision or hearing based on history and physical exam.
Incidence of Parkinson's disease in two or more first degree relatives.
Dementia not due to PD or severe dementia with MMSE less than 15.
Neurological disorder other than PD that would effect protocol (e.g. stroke, Alzheimer's disease).
Laboratory tests with clinically significant abnormalities.
History of an abnormal MRI.
Pregnancy or breast feeding.
Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual NIH RSC limits.
Any conditions that increase risk for MRI (pacemaker, metallic foreign body, claustrophobia, etc.).
Any medical condition that in the opinion of the investigators would interfere with the safe conduct of the study.
Severe hypertension. The subject may be on anti-hypertensive medications. The initial screening must show no more than moderate hypertension - i.e. less than 160/95. In addition, the subject must have normal laboratory values (e.g., BUN, creatinine, urinalysis, and ECG) to document lack of end organ damage. On baseline evaluation on the day of the scan (i.e., before injection of tracer), the subject must be asymptomatic (no headache, dizziness, neurological symptoms, or blurred vision) AND have sustained BP less than 180/100.
Inability to provide consent.
Smoking within 6 months prior to enrollment in the study.
EXCLUSION CRITERIA - PATIENTS:
Secondary cause of Parkinsonism, e.g. Wilson's disease, neuroleptic use.
Psychiatric disease that would, in judgment of the investigator, interfere with the safe conduct of the study.
Current psychiatric illness except for depression.
Severe depressive symptoms with BDI 16+.
Substance abuse, severe systemic disease, poor vision or hearing based on history and physical exam.
Dementia not due to PD or severe dementia with MMSE less than 15.
Neurological disorder other than PD that would effect protocol (e.g. stroke, Alzheimer's disease).
Laboratory tests with clinically significant abnormalities.
History of an abnormal MRI.
Pregnancy or breast feeding.
Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual NIH RSC limits.
Any conditions that increase risk for MRI (pacemaker, metallic foreign body, claustrophobia, etc.).
Any medical condition that in the opinion of the investigators would interfere with the safe conduct of the study.
Severe hypertension. The subject may be on anti-hypertensive medications. The initial screening must show no more than moderate hypertension - i.e. less than 160/95. In addition, the subject must have normal laboratory values (e.g., BUN, creatinine, urinalysis, and ECG) to document lack of end organ damage. On baseline evaluation on the day of the scan (i.e., before injection of tracer), the subject must be asymptomatic (no headache, dizziness, neurological symptoms, or blurred vision) AND have sustained BP less than 180/100.
Inability to provide consent.
Smoking within 6 months prior to enrollment in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 050011
- 05-M-0011
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad de Parkinson
-
ProgenaBiomeReclutamientoEnfermedad de Parkinson | Enfermedad de Parkinson con demencia | Síndrome de Parkinson-Demencia | Enfermedad de Parkinson 2 | Enfermedad de Parkinson 3 | Enfermedad de Parkinson 4Estados Unidos
-
National Heart, Lung, and Blood Institute (NHLBI)TerminadoEnfermedad de Parkinson 6, inicio temprano | Enfermedad de Parkinson (autosómica recesiva, aparición temprana) 7, humana | Enfermedad de Parkinson Autosómica Recesiva, Inicio Temprano | Enfermedad de Parkinson, autosómica recesiva de aparición temprana, digénica, Pink1/Dj1Estados Unidos
-
Assiut UniversityAún no reclutandoMri en Parkinson
-
Medical College of WisconsinRetirado
-
Hacettepe UniversityTerminadoEnfermedad de Parkinson idiopáticaPavo
-
Pôle Saint HélierRennes University Hospital; Réseau Parkinson BretagneTerminadoEnfermedad de Parkinson | Síndrome de ParkinsonFrancia
-
UCB PharmaTerminadoEnfermedad de Parkinson idiopáticaAlemania
-
King's College LondonGlaxoSmithKlineTerminadoEnfermedad de Parkinson | Enfermedad de Parkinson idiopática | Enfermedad de Parkinson, PARK8Reino Unido
-
UCB PharmaTerminadoENFERMEDAD DE PARKINSON IDIOPÁTICAPorcelana
-
Samuel Vilchez, PhDNational Autonomous University of Nicaragua; Wake Forest University; GID BIO, Inc. y otros colaboradoresTerminadoEnfermedad de Parkinson y parkinsonismo | Enfermedad de Parkinson idiopáticaNicaragua